National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.


NCPE Assessment Process Complete
Rapid review commissioned 23/10/2018
Rapid review completed 16/11/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 21/11/2018
Pre-submission consultation with Applicant 17/12/2018
Submission received from Applicant 23/05/2019
HTA assessment commenced 12/08/2019
Preliminary review sent to Applicant 04/10/2019
NCPE assessment re-commenced 01/11/2019
Current Status NCPE assessment ongoing